Florepizol - Oncodesign Precision Medicine
Alternative Names: Anti-EGFR PET radiotracer - Oncodesign Precision MedicineLatest Information Update: 07 May 2023
At a glance
- Originator Oncodesign Precision Medicine
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Non-small cell lung cancer
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 24 Apr 2023 Oncodesign Precision Medicine plans to launch florepizol by 2025 (Oncodesign Precision Medicine, April 2023)
- 24 Apr 2023 Oncodesign Precision Medicine plans a phase III trial for florepizol (Oncodesign Precision Medicine, April 2023)
- 24 Apr 2023 Florepizol - Oncodesign Precision Medicine is available for licensing as of 13 Apr 2023